Targeting TGF-β signal transduction for fibrosis and cancer therapy

Dandan Peng1, Minyang Fu1, Manni Wang1

  • 1Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, 610041, PR, Sichuan, China.

Molecular Cancer
|April 24, 2022
PubMed

Insights

Transforming growth factor beta (TGF-β) plays a dual role in fibrosis and cancer. Targeting TGF-β signaling offers therapeutic potential, but challenges remain due to cytotoxicity concerns.

Area of Science:

  • Cell biology
  • Molecular biology
  • Oncology

Background:

  • Transforming growth factor beta (TGF-β) is crucial for embryonic development, immune function, and tissue repair.
  • TGF-β exhibits complex, context-dependent roles in fibrosis and cancer, acting as both an inhibitor and promoter.
  • Overexpression of TGF-β under pathological conditions drives fibrosis and cancer progression via mechanisms like epithelial-mesenchymal transition (EMT).

Purpose of the Study:

  • To review the biological functions of TGF-β.
  • To elucidate the dual role of TGF-β in fibrosis and tumorigenesis.
  • To discuss the clinical applications and challenges of TGF-β-targeting therapies.

Main Methods:

  • Literature review of TGF-β's biological processes.
  • Analysis of TGF-β's involvement in fibrotic and cancerous conditions.
  • Examination of clinical studies on TGF-β-targeted therapeutics.

Main Results:

  • TGF-β signaling is implicated in epithelial-mesenchymal transition (EMT), extracellular matrix (ECM) deposition, and cancer-associated fibroblast (CAF) formation.
  • The therapeutic targeting of TGF-β signaling is a promising strategy for treating fibrosis and cancer.
  • Development of TGF-β therapeutics is hindered by potential systemic cytotoxicity.

Conclusions:

  • TGF-β is a critical mediator in fibrosis and cancer development.
  • Targeting TGF-β pathways holds therapeutic promise but requires careful consideration of side effects.
  • Further research is needed to overcome the challenges in developing safe and effective TGF-β-targeting drugs.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.8K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.8K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.9K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K